Market News
Recent Developments
New product launches
- In April 2023, Alnylam Pharmaceuticals, Inc., a pharmaceutical company, and Regeneron Pharmaceuticals, Inc., a pharmaceutical company, announced positive interim results from the ongoing single-ascending portion of the Phase 1 trial of ALN-APP, an experimental RNAi therapeutic amyloid -Forerunne, targeting protein (APP) in development for the treatment of Alzheimer\'s disease and cerebral amyloid angiopathy (CAA).
- In March 2023, OliX Pharmaceuticals, Inc., a pharmaceutical company, the first patient dosage in a Phase 1 clinical study marked a significant milestone. This study focuses on a groundbreaking RNAi therapy that has the potential to prevent and treat age-related macular degeneration (AMD).
Acquisition and partnerships
- In December 2022, GSK plc, a pharmaceutical company, and Wave Life Sciences Ltd., a clinical-stage genetic medicine company committed to providing life-changing treatments for people with devastating diseases, announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave\'s preclinical RNA editing program, Combating Alpha-1 Antitrypsin Deficiency (AATD), WVE-006. The research cooperation initially has a four-year research period. It combines GSK\'s unique human genetics insights, global development, and commercial capabilities with PRISMTM, Wave\'s proprietary discovery and drug development platform.
- In June 2020, Evox Therapeutics Ltd., a leading exosome therapeutics company, is pleased to announce a research collaboration and licensing agreement with Eli Lilly and Company to develop the proprietary DeliverEX RNA interference (RNAi) platform from Evox to develop and use antisense oligonucleotide (ASO) drug payloads for the potential treatment of neurological disorders.
U.S.: 
U.K. : 
India : 
